Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2008-05-13
2008-05-13
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S192100, C530S300000, C435S006120
Reexamination Certificate
active
07371391
ABSTRACT:
Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.
REFERENCES:
patent: 5618536 (1997-04-01), Lowy et al.
patent: 5855891 (1999-01-01), Lowy et al.
patent: 6228368 (2001-05-01), Gissmann et al.
patent: 4435907 (1996-04-01), None
patent: WO-93/02184 (1993-02-01), None
patent: WO-93/20844 (1993-10-01), None
patent: WO-94/00152 (1994-01-01), None
patent: WO-94/05792 (1994-03-01), None
patent: WO-96/11274 (1996-04-01), None
patent: WO-98/42847 (1998-10-01), None
patent: WO-99/10557 (1999-01-01), None
Altmann, et al., “Towards HPV Vaccination,”Viruses and Cancer, Minson et al.., (eds.) Cambridge University Press, (1994) pp. 71-80.
Arbeit, et al., “Progressive Squamous Epithelial Neoplasia in K14-Human Papilliomavirus Type 16 Transgenic Mice,”J. Virol.68:4358-4364 (1994).
Auewarakul, et al., “Targeted Expression of the E6 and E7 Oncogenes of Human Papillomavirus Type 16 in the epidermis of Transgenic Mice Elicits Generalized Epiderman Hpreplasia Involving Autocrine Factors,”Mol. Cell. Biol.14:8250-8258 (1994).
Ausebel, et al., (eds.),Protocols in Molecular Biology, John Wiley & sons, Inc. (1994-1997).
Barbosa, et al., “In Vitro Biological Activities of the E6 and E7 Genes Vary among Human Papillomaviruses of Different Oncogenic Potentional,”J. Virol.65:292-298 (1991).
Campo, “Vaccination Against Papillomavirus in Cattle,”Curr. Top. in Microbiol. and Immunol.186:225-266 (1994).
Crum, “Human Papillomavirus Type 16 and Early Cervical Neoplasia,”New Eng. J. Med.310:880-883 (1984).
Ikenberg, “Human Papillomavirus DNA in Invasive Genital Carcinomas,” In Gross, et al., (eds.) Genital Papillomavirus Infections, Springer Verlag: Berlin, pp. 87-112, 1990.
Kaur, et al., “Immortalization of Primary Human Epithelial Cells by Cloned Cervical Carcinoma DNA Containing Human Papillomavirus Type 16 E6/E7 Open Reading Frames,”J. Gen. Virol.70:1261-1266 (1989).
Kirnbauer, et al., “Efficient Self-Assembly of Human Papillomavirus Type 16 L1 and L1-L2 into Virus-Like Particles,”J. Virol.67:6929-6936 (1994).
Kirnbauer, et al., “Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic,”Proc. Natl. Acad. Sci(USA), 99:12180-12814 (1992).
Li, et al., “Expression of the Human Papillomavirus Type 11 L1 Capsid Protein inEscherichia coli: Characterization of Protein Domains L involved in DNA Binding and Capsid Assembly,”J. Virol.71:2988-2995 (1997).
Müler, et al., “Chimeric Papillomavirus-like Particle,”Virol.234:93-111 (1997).
Painsil, et al., “Carboxyl Terminus of Bovine Papillomavirus Type-1 L1 Protein is Not Required for Capsid Formation,”Virol.223:238-244 (1996).
Prober, et al., “A System of Rapid DNA Sequencing with Fluorescent Chain-Terminating Dideoxynucleotides,”Science238:336-341 (1987).
Rose, et al., “Expressing of Human Papillomavirus Type 11 L1 Protein in Insect Cells: In Vitro and In Vitro Assembly of Virus like Particles,”J. Virol.67(4):1936-1944 (1992).
Rose, et al., “Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles,”J. Gen Virol.75:2445-2449 (1994).
Sambrook, et al., (eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press: Cold Spring Harbor, NY (1989).
Sasagawa, et al., “Synthesis and Assembly of Virus-like Particles of Human Papillomaviruses Type 6 and Type 16 in Fission Yeast Schizosaccharomycees pombe,”Virology206:126-195 (1995).
Schlegel, et al., “Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma,”EMBO J., 7:3181-3187 (1988).
Tindle and Frazer, “Immune Response to Human Papillomaviruses and the Prospects for Human Papillomavirus-Specification Immunisation,”Curr. Top. in Microbiol. and Immunol.186:217-253 (1994).
Volpers, et al., “Binding and internalization of Human Papillomavirus Type 33 Virus-Like Particles by Eukaryotic Cells,”J. Virol.69:3258-3264 (1995).
Wettstein, et al., “State of Viral DNA and Gene Expression in Benign vs. Malignant Tumors,” Papilloma Viruses and Human Cancer, Pfister (Ed.), CRC Press: Boca Raton, FL 1990, pp. 155-179.
Zhou, et al., “Expression of Vaccinia Recombinant HPV 16 L1 and L2 ORF Proteins in Epithelial Cells is Sufficient for Assembly of HPV Virion-like Particles,”Virology185:251-257 (1991).
Zhou, et al., “Synthesis and assembly of infectious bovine papillomavirus particles in vitro,”J. Gen. Virol.74:762-769 (1993).
Gissmann Lutz
Muller Martin
Loyola University of Chicago
Marsahall, Gerstein & Borun LLP
Salimi Ali R.
LandOfFree
Papilloma virus capsomere vaccine formulations and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Papilloma virus capsomere vaccine formulations and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Papilloma virus capsomere vaccine formulations and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2749004